Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Integrated Personalized Prediction Model Identifies a Subgroup of Wild-Type TP53 therapy-Related Myeloid Neoplasm Patients with Poor Outcome

Blood (2022) 140 (Supplement 1): 6964–6965.

https://doi.org/10.1182/blood-2022-168349

Published: 2022

Journal Articles

Senolytic Therapy Can Reverse Senescent Bone Marrow Stroma of Therapy-Related Myeloid Neoplasm

Monika M Kutyna, Chung Hoow Kok, Yoon Lim, David Campbell, Sharon Paton, Chloe AL Thompson-Peach, Kelly SY Lim, Timothy Hughes, Sharad Kumar, Daniel Thomas, Stan Gronthos, Devendra Hiwase

Blood (2022) 140 (Supplement 1): 9755–9756.

https://doi.org/10.1182/blood-2022-167994

Published: 2022

Journal Articles

TP53 Mutation Status Defines a Distinct Clinicopathological Entity of Therapy-Related Myeloid Neoplasm, Characterized By Genomic Instability and Extremely Poor Outcome

Blood (2022) 140 (Supplement 1): 9798–9799.

https://doi.org/10.1182/blood-2022-165859

Published: 2022

Journal Articles

Distinct Senescent Bone Marrow Microenvironment in Therapy-Related Myeloid Neoplasms

Monika M Kutyna, Chung Hoow Kok, Sharon Paton, Dimitrios Cakouros, Agnieszka Arthur, Timothy P. Hughes, Daniel Thomas, David Campbell, Stan Gronthos, Devendra Hiwase

Blood (2021) 138 (Supplement 1): 2585.

https://doi.org/10.1182/blood-2021-148215

Published: 2021

Journal Articles

Unexpected High Frequency of Pathogenic Germline Variants in Older Adults with Primary Myelodysplastic Syndrome

Christopher N Hahn, Simone K. Feurstein, Deepak Singhal, Monika M Kutyna, Rakchha Chhetri, Amilia Wee, Daniel Thomas, Hamish S Scott, Devendra Hiwase

Blood (2021) 138 (Supplement 1): 2594.

https://doi.org/10.1182/blood-2021-154514

Published: 2021

Journal Articles

Frequency of Chromosomal Translocations Are Significantly Higher in Therapy Related Myeloid Neoplasm As Compared to Primary MDS

Jamie Choong, Monika M Kutyna, Rakchha Chhetri, Sarah Moore, Devendra Hiwase

Blood (2021) 138 (Supplement 1): 1532.

https://doi.org/10.1182/blood-2021-154523

Published: 2021

Journal Articles

Hypomethylating Therapy Does Not Improve Outcome of Therapy-Related Myeloid Neoplasm Including TP53 Mutated and Complex Karyotype Subgroups

Rakchha Chhetri, Kirsty Sharplin, William Proudman, Monika M Kutyna, Siddarth Nayar, Deepak Singhal, David M Ross, Michelle Damin, Akash Kalro, Peter G Bardy, Daniel Thomas, Mithun V. Shah, Devendra Hiwase

Blood (2021) 138 (Supplement 1): 3702.

https://doi.org/10.1182/blood-2021-154094

Published: 2021

Journal Articles

Burden of Cardiovascular Events and Bleeding Is High in Myelodysplastic Syndromes

Rakchha Chhetri, MBBS, Oisin Friel, MBBS, Monika M Kutyna, MSc, Kathleen Pao Lynn Cheok, MBBS, Li Yan A Wee, BSc (Hons), Hossam Amin, Rebecca Thompson, B Pharm, Deepak Singhal, MBBS,MDFRACP,FRCPA, Kirsty M Sharplin, MBBS, Devendra K Hiwase, MBBS, MD FRACP, FRCPA, PhD

Blood (2020) 136 (Supplement 1): 34–35.

https://doi.org/10.1182/blood-2020-143319

Published: 2020

Journal Articles

Therapy-Related Myeloid Neoplasm Has a Distinct Pro-Inflammatory Bone Marrow Microenvironment and Delayed DNA Damage Repair

Monika M Kutyna, MSc, Li Yan A Wee, BSc (Hons), Sharon Paton, BSc, Dimitrios Cakouros, PhD, Agnieszka Arthur, PhD, Rakchha Chhetri, MBBS, Andreas W Schreiber, PhD, Chung Hoow Kok, PhD BSc, Deepak Singhal, MBBS,MDFRACP,FRCPA, Daniel Thomas, MD PhD, Timothy P. Hughes, MDMBBS,FRACP,FRCPA, David Campbell, PhD B.M.B.S., F.R.A.C.S., F.A.Oth.A, Stan Gronthos, PhD, Devendra K Hiwase, MBBS, MD FRACP, FRCPA, PhD

Blood (2020) 136 (Supplement 1): 37–38.

https://doi.org/10.1182/blood-2020-137277

Published: 2020

Journal Articles

Aberrant Bone Marrow Microenvironment in Therapy Related Myeloid Neoplasm (t-MN)

Monika M Kutyna, MSc, Amilia Wee, BSc (Hons), Sharon Paton, BSc, Dimitrios Cakouros, PhD, Agnes Arthur, PhD, Rakchha Chhetri, MBBS, Deepak Singhal, MBBS, MD FRACP, FRCPA, Stan Gronthos, PhD, Devendra K Hiwase, MBBS, MD FRACP, FRCPA, PhD

Blood (2019) 134 (Supplement_1): 1694.

https://doi.org/10.1182/blood-2019-126457

Published: 2019

Journal Articles

Deleterious Germline Variants, Especially in the DNA Repair Pathway, Are Common in Patients with Non-Related Multiple Cancers, One of Them Being Hematological Malignancy

Blood (2019) 134 (Supplement_1): 1704.

https://doi.org/10.1182/blood-2019-126462

Published: 2019

Journal Articles

Red Cell Alloimmunisation Is Associated with Increased Red Cell Transfusion Requirements in Myelodysplastic Syndrome

Rakchha Chhetri, MBBS, Amilia Wee, BSc (Hons), Romi Sinha, MBBS, Monika M Kutyna, MSc, Soumya Gupta, Lakshmi Nath, MDDM,FRCPA, Shriram V. Nath, MDDM, FRCPA, FRACP, Nicholas Wickham, FRCPA, FRACP, FRCPath, Ian D Lewis, MBBS,PhD, David M Ross, Luen Bik To, MBBS, FRACP, FRCPA, PhD, Deepak Singhal, MBBS, MDFRACP, FRCPA, David John Roxby, B App Sc, M App Sc, ARCPA, Devendra K Hiwase, MBBS, MD FRACP, FRCPA, PhD

Blood (2018) 132 (Supplement 1): 1826.

https://doi.org/10.1182/blood-2018-99-115848

Published: 2018

Journal Articles

Therapy-Related Myeloid Neoplasms (T-MN) and Primary MDS (PMDS) Patients with Very Low (VL) or Low (L) IPSS-R Score Share Clinical and Biological Characteristics and Have Similar Outcome

Blood (2018) 132 (Supplement 1): 3078.

https://doi.org/10.1182/blood-2018-99-115828

Published: 2018

Journal Articles

Genetic Predisposition to Therapy-Related Myeloid Neoplasm By Rare, Deleterious Germline Variants in DNA Repair Pathway and Myeloid Driver Genes

Blood (2018) 132 (Supplement 1): 1802.

https://doi.org/10.1182/blood-2018-99-117815

Published: 2018

Journal Articles

Presence of Rare Germline Variants in Fanconi Anaemia Pathway Genes Confers a Poor Prognosis Comparable to TP53 Mutations in Therapy-Related Myeloid Neoplasms

Blood (2017) 130 (Supplement 1): 4231.

https://doi.org/10.1182/blood.V130.Suppl_1.4231.4231

Published: 2017

Journal Articles

Red Cell Alloimmunisation Is Associated with Development of Autoantibodies and Increased Red Cell Transfusion Requirements in Myelodysplastic Syndromes (MDS)

Deepak Singhal, MBBS, MD FRCPA, FRACP, Monika M Kutyna, MSc, Rakchha Chhetri, MBBS, Amilia Wee, BSc (Hons), Sophia Hague, Lakshmi Nath, MDDM,FRCPA, Shriram V Nath, MBBS, DM, FRCPA, Romi Sinha, MBBS, Nicholas Wickham, FRCPA,FRACP,FRCPath, Ian D Lewis, MBBS, PhD FRACP, FRCPA, David M Ross, MBBS, PhD FRACP, FRCPA, Peter G Bardy, MBBS, FRACP, FRCPA, FRCPath, Luen Bik To, MBBS, FRACP, FRCPA, PhD, John Reynolds, PhD, Erica Wood, David John Roxby, Devendra K Hiwase, MBBS, MD FRACP, FRCPA, PhD

Blood (2017) 130 (Supplement 1): 2411.

https://doi.org/10.1182/blood.V130.Suppl_1.2411.2411

Published: 2017

Journal Articles

Duplication on Chromosome 14q Identified in Familial Predisposition to Myeloid Malignancies and Myeloproliferative Neoplasms

Christopher N Hahn, PhD, Amilia Wee, BSc (Hons), Milena Babic, BMPharBio (Hons), Jinghua Feng, PhD, Paul Wang, Monika M Kutyna, MSc, Sarah Moore, BSc (Hon), FFSc (RCPA), Anna L Brown, PhD, Richard D'Andrea, BSc,PhD, Deepak Singhal, MBBS, MD FRCPA, FRACP, Andreas Schreiber, PhD, Pratyush Giri, MD, David M Ross, MBBS, PhD FRACP, FRCPA, Devendra K Hiwase, MBBS, MD FRACP, FRCPA, PhD, Hamish S Scott, BSc, PhD FFSc (RCPA), FAHMS

Blood (2017) 130 (Supplement 1): 492.

https://doi.org/10.1182/blood.V130.Suppl_1.492.492

Published: 2017

Journal Articles

The Frequency of Genetic Mutations in T-MN Is High and Comparable to Primary MDS but the Spectrum Is Different

Blood (2016) 128 (22): 3157.

https://doi.org/10.1182/blood.V128.22.3157.3157

Published: 2016

Journal Articles

RBC-Transfusion Dependency Improves the Prognostic Value of the Revised-IPSS in MDS Patients: Analysis of South Australian and Dusseldorf MDS Registries

Deepak Singhal, MD FRCPA, Corinna Strupp, Rakchha Chhetri, MBBS, Monika M Kutyna, MSc, L Amilia Wee, B.Sc(Hons), Shriram V. Nath, FRCPA, DM, MD, Nicholas Wickham, FRCPA, FRACP, FRCPath, Chi-hung Hui, MBBS, MRCP, FRCPath, FRACP, FRCPA, James X Gray, MD PhD, David M. Ross, MBBS, PhD FRACP, FRCPA, Ian D Lewis, MBBS, PhD FRACP, FRCPA, Peter G Bardy, MBBS, FRACP, FRCPA, John Reynolds, PhD, Luen Bik To, MBBS, PhD, Devendra K Hiwase, MBBS, MD FRACP, FRCPA, PhD, Ulrich Germing

Blood (2016) 128 (22): 1998.

https://doi.org/10.1182/blood.V128.22.1998.1998

Published: 2016

Journal Articles

Rare and Common Germline Variants Contribute to Occurrence of Myelodysplastic Syndrome

Blood (2015) 126 (23): 1644.

https://doi.org/10.1182/blood.V126.23.1644.1644

Published: 2015

NARROW

Integrated Personalized Prediction Model Identifies a Subgroup of Wild-Type TP53 therapy-Related Myeloid Neoplasm Patients with Poor Outcome

Senolytic Therapy Can Reverse Senescent Bone Marrow Stroma of Therapy-Related Myeloid Neoplasm

TP53 Mutation Status Defines a Distinct Clinicopathological Entity of Therapy-Related Myeloid Neoplasm, Characterized By Genomic Instability and Extremely Poor Outcome

Distinct Senescent Bone Marrow Microenvironment in Therapy-Related Myeloid Neoplasms

Unexpected High Frequency of Pathogenic Germline Variants in Older Adults with Primary Myelodysplastic Syndrome

Frequency of Chromosomal Translocations Are Significantly Higher in Therapy Related Myeloid Neoplasm As Compared to Primary MDS

Hypomethylating Therapy Does Not Improve Outcome of Therapy-Related Myeloid Neoplasm Including TP53 Mutated and Complex Karyotype Subgroups

Burden of Cardiovascular Events and Bleeding Is High in Myelodysplastic Syndromes

Therapy-Related Myeloid Neoplasm Has a Distinct Pro-Inflammatory Bone Marrow Microenvironment and Delayed DNA Damage Repair

Aberrant Bone Marrow Microenvironment in Therapy Related Myeloid Neoplasm (t-MN)

Deleterious Germline Variants, Especially in the DNA Repair Pathway, Are Common in Patients with Non-Related Multiple Cancers, One of Them Being Hematological Malignancy

Red Cell Alloimmunisation Is Associated with Increased Red Cell Transfusion Requirements in Myelodysplastic Syndrome

Therapy-Related Myeloid Neoplasms (T-MN) and Primary MDS (PMDS) Patients with Very Low (VL) or Low (L) IPSS-R Score Share Clinical and Biological Characteristics and Have Similar Outcome

Genetic Predisposition to Therapy-Related Myeloid Neoplasm By Rare, Deleterious Germline Variants in DNA Repair Pathway and Myeloid Driver Genes

Presence of Rare Germline Variants in Fanconi Anaemia Pathway Genes Confers a Poor Prognosis Comparable to TP53 Mutations in Therapy-Related Myeloid Neoplasms

Red Cell Alloimmunisation Is Associated with Development of Autoantibodies and Increased Red Cell Transfusion Requirements in Myelodysplastic Syndromes (MDS)

Duplication on Chromosome 14q Identified in Familial Predisposition to Myeloid Malignancies and Myeloproliferative Neoplasms

The Frequency of Genetic Mutations in T-MN Is High and Comparable to Primary MDS but the Spectrum Is Different

RBC-Transfusion Dependency Improves the Prognostic Value of the Revised-IPSS in MDS Patients: Analysis of South Australian and Dusseldorf MDS Registries

Rare and Common Germline Variants Contribute to Occurrence of Myelodysplastic Syndrome

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only